# SSTR5

## Overview
The SSTR5 gene encodes the somatostatin receptor 5, a member of the G protein-coupled receptor (GPCR) family, which is characterized by its seven transmembrane-spanning domains. This receptor is involved in a variety of physiological processes, primarily through its role in inhibiting adenylyl cyclase activity, which leads to decreased levels of cyclic adenosine monophosphate (cAMP) and intracellular calcium. SSTR5 is expressed in several tissues, including the pituitary gland, pancreas, and certain brain regions, where it modulates hormone secretion, cell proliferation, and neurotransmission. The receptor's ability to form heterodimers with other somatostatin receptor subtypes and dopamine receptors further influences its functional properties and therapeutic potential, particularly in conditions such as acromegaly and certain neuropsychiatric disorders (Günther2018International; Benali2000Somatostatin; Kumar2023Somatostatin).

## Structure
The somatostatin receptor 5 (SSTR5) is a G protein-coupled receptor (GPCR) characterized by its seven transmembrane-spanning domains, typical of GPCRs (Benali2000Somatostatin). The primary structure of SSTR5 includes a unique substitution in the transmembrane region 6, where a conserved tyrosine in other somatostatin receptors is replaced by a phenylalanine. This substitution is significant for its ligand-binding characteristics, as mutating this phenylalanine to a tyrosine increases the receptor's affinity for somatostatin, highlighting the importance of a single hydroxyl group in enhancing binding (Reisine1995Somatostatin).

SSTR5 exhibits a lower sequence identity between rat and human versions compared to other somatostatin receptors, with only 81% identity, which may contribute to differences in ligand selectivity (Reisine1995Somatostatin). The receptor is involved in various signaling pathways, including the inhibition of adenylyl cyclase and the suppression of cyclic adenosine monophosphate (cAMP) formation, as well as the inhibition of mitogen-activated protein kinases (MAPKs) (Kumar2023Somatostatin). Post-translational modifications such as phosphorylation and glycosylation are common in GPCRs like SSTR5, potentially affecting its function and localization. Alternative splicing may result in different isoforms, influencing its activity and interaction with ligands.

## Function
Somatostatin receptor 5 (SSTR5) is a G protein-coupled receptor that plays a crucial role in regulating various cellular and physiological processes. In healthy human cells, SSTR5 primarily functions by inhibiting adenylyl cyclase activity through coupling with Gi proteins, leading to reduced cAMP accumulation and decreased intracellular calcium levels (Günther2018International; Benali2000Somatostatin). This receptor is involved in the modulation of hormone secretion, particularly in the pituitary gland, where it regulates growth hormone (GH) and thyroid-stimulating hormone (TSH) secretion (Shimon1997Somatostatin).

SSTR5 also influences cell proliferation by activating signaling pathways such as the MAPK pathway, which is associated with G1 cell cycle arrest (Patel1999Somatostatin). It exerts antiproliferative effects by activating neuronal nitric oxide synthase (NOS) via p60src kinase and inhibiting the mTOR pathway, which decreases cell growth and proliferation (Günther2018International). Additionally, SSTR5 is involved in the regulation of insulin secretion from pancreatic islets, contributing to glucose homeostasis (Patel1999Somatostatin).

SSTR5 is expressed in various tissues, including the anterior pituitary, pancreas, and specific brain regions, where it modulates endocrine and exocrine secretions, cell proliferation, and neurotransmission (Günther2018International).

## Clinical Significance
Mutations and alterations in the SSTR5 gene have been implicated in several diseases and conditions. In the context of neuropsychiatric disorders, the SSTR5 gene is considered a candidate gene for bipolar affective disorder (BPAD). Studies have identified novel single nucleotide polymorphisms (SNPs) in the SSTR5 gene, such as Leu48Met, Ala52Val, and Pro335Leu, which have shown associations with BPAD, particularly in the UK population (Nyegaard2002Novel). The gene's interaction with the dopamine D2 receptor (DRD2) is significant, as DRD2 antagonists are used in treating manic symptoms and schizophrenia (Nyegaard2002Novel).

In oncology, SSTR5 polymorphisms have been linked to pancreatic cancer risk and survival. The P109S variant allele is associated with an increased risk of pancreatic cancer, and certain genotypes like P335L CC and P109S CC are linked to shorter survival durations in patients with resectable disease (Li2011Association). The SSTR5 gene is also involved in the pathogenesis of somatotroph pituitary adenomas, as seen in a case study of a patient with acromegaly and autosomal dominant polycystic kidney disease, where a p.L48M substitution was identified (Syro2011Somatotroph).

## Interactions
SSTR5, or somatostatin receptor 5, is known to participate in various interactions with other proteins, influencing multiple signaling pathways. SSTR5 can form heterodimers with other somatostatin receptor subtypes, such as SSTR2, which can alter their functional properties and enhance signaling pathways. This interaction is particularly noted in the context of pituitary tumors and acromegaly, where the heterodimerization of SSTR2 and SSTR5 may enhance therapeutic responses (Cervia2003Biological; Kumar2023Somatostatin).

SSTR5 also interacts with dopamine receptors, forming heterodimers with D2R, which can change the pharmacological properties compared to native receptors. This interaction has been explored for potential therapeutic strategies, particularly in the treatment of acromegaly, where chimeric molecules known as dopastatins have been developed to target these heterodimers (Kumar2023Somatostatin).

In addition to these interactions, SSTR5 is involved in the regulation of intracellular signaling pathways, such as the inhibition of the MAP kinase Erk1/2 pathway and the modulation of calcium and potassium currents. These interactions contribute to its role in inhibiting hormone secretion and cell proliferation (Cordelier1997Characterization; Benali2000Somatostatin).


## References


[1. (Reisine1995Somatostatin) T. Reisine. Somatostatin receptors. American Journal of Physiology-Gastrointestinal and Liver Physiology, 269(6):G813–G820, December 1995. URL: http://dx.doi.org/10.1152/ajpgi.1995.269.6.g813, doi:10.1152/ajpgi.1995.269.6.g813. This article has 10 citations.](https://doi.org/10.1152/ajpgi.1995.269.6.g813)

[2. (Benali2000Somatostatin) Naoual Benali, Geraldine Ferjoux, Elena Puente, Louis Buscail, and Christiane Susini. Somatostatin receptors. Digestion, 62(Suppl. 1):27–32, 2000. URL: http://dx.doi.org/10.1159/000051852, doi:10.1159/000051852. This article has 68 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000051852)

[3. (Patel1999Somatostatin) Yogesh C. Patel. Somatostatin and its receptor family. Frontiers in Neuroendocrinology, 20(3):157–198, July 1999. URL: http://dx.doi.org/10.1006/frne.1999.0183, doi:10.1006/frne.1999.0183. This article has 1252 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/frne.1999.0183)

[4. (Kumar2023Somatostatin) Ujendra Kumar. Somatostatin and somatostatin receptors in tumour biology. International Journal of Molecular Sciences, 25(1):436, December 2023. URL: http://dx.doi.org/10.3390/ijms25010436, doi:10.3390/ijms25010436. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25010436)

[5. (Günther2018International) Thomas Günther, Giovanni Tulipano, Pascal Dournaud, Corinne Bousquet, Zsolt Csaba, Hans-Jürgen Kreienkamp, Amelie Lupp, Márta Korbonits, Justo P. Castaño, Hans-Jürgen Wester, Michael Culler, Shlomo Melmed, and Stefan Schulz. International union of basic and clinical pharmacology. cv. somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacological Reviews, 70(4):763–835, September 2018. URL: http://dx.doi.org/10.1124/pr.117.015388, doi:10.1124/pr.117.015388. This article has 167 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1124/pr.117.015388)

[6. (Syro2011Somatotroph) Luis V. Syro, Jamie L. Sundsbak, Bernd W. Scheithauer, Rodrigo A. Toledo, Mauricio Camargo, Christina M. Heyer, Tomoko Sekiya, Humberto Uribe, Jorge I. Escobar, Martin Vasquez, Fabio Rotondo, Sergio P. A. Toledo, Kalman Kovacs, Eva Horvath, Dusica Babovic-Vuksanovic, and Peter C. Harris. Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: sstr5 polymorphism and pkd1 mutation. Pituitary, 15(3):342–349, July 2011. URL: http://dx.doi.org/10.1007/s11102-011-0325-0, doi:10.1007/s11102-011-0325-0. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11102-011-0325-0)

[7. (Cervia2003Biological) D Cervia, P Zizzari, B Pavan, E Schuepbach, D Langenegger, D Hoyer, C Biondi, J Epelbaum, and P Bagnoli. Biological activity of somatostatin receptors in gc rat tumour somatotrophs: evidence with sst1–sst5 receptor-selective nonpeptidyl agonists. Neuropharmacology, 44(5):672–685, April 2003. URL: http://dx.doi.org/10.1016/s0028-3908(03)00031-5, doi:10.1016/s0028-3908(03)00031-5. This article has 29 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0028-3908(03)00031-5)

[8. (Nyegaard2002Novel) M Nyegaard, A D Børglum, T G Bruun, D A Collier, C Russ, O Mors, H Ewald, and T A Kruse. Novel polymorphisms in the somatostatin receptor 5 (sstr5) gene associated with bipolar affective disorder. Molecular Psychiatry, 7(7):745–754, August 2002. URL: http://dx.doi.org/10.1038/sj.mp.4001049, doi:10.1038/sj.mp.4001049. This article has 26 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/sj.mp.4001049)

[9. (Cordelier1997Characterization) Pierre Cordelier, Jean-Pierre Estève, Corinne Bousquet, Nathalie Delesque, Anne-Marie O’Carroll, Andrew V. Schally, Nicole Vaysse, Christiane Susini, and Louis Buscail. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proceedings of the National Academy of Sciences, 94(17):9343–9348, August 1997. URL: http://dx.doi.org/10.1073/pnas.94.17.9343, doi:10.1073/pnas.94.17.9343. This article has 105 citations.](https://doi.org/10.1073/pnas.94.17.9343)

[10. (Shimon1997Somatostatin) I Shimon, J E Taylor, J Z Dong, R A Bitonte, S Kim, B Morgan, D H Coy, M D Culler, and S Melmed. Somatostatin receptor subtype specificity in human fetal pituitary cultures. differential role of sstr2 and sstr5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. Journal of Clinical Investigation, 99(4):789–798, February 1997. URL: http://dx.doi.org/10.1172/jci119225, doi:10.1172/jci119225. This article has 212 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci119225)

[11. (Li2011Association) Donghui Li, Motofumi Tanaka, F. Charles Brunicardi, William E. Fisher, Richard A Gibbs, and Marie‐Claude Gingras. Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer, 117(13):2863–2872, January 2011. URL: http://dx.doi.org/10.1002/cncr.25858, doi:10.1002/cncr.25858. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/cncr.25858)